Jinyu Bio subsidiary secures new veterinary drug approval

Jinyu Bio-Technology Co., Ltd. (SSE:600201) announced that its wholly-owned subsidiary, Jinyu Baoling Biological Pharmaceuticals Co., Ltd., has obtained a new veterinary drug registration certificate for its bovine mycoplasma live vaccine (HB150 strain). Approved by the Ministry of Agriculture and Rural Affairs, the vaccine, classified as a Class I new veterinary drug, targets respiratory diseases caused by bovine mycoplasma. Immunization provides protection for eight months after 28 days post inoculation. The company invested approximately RMB 13 million in the development of the product. Jinyu Baoling will now proceed with application for batch release.